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http://dx.doi.org/10.1016/j.fjs.2013.Summary Tumor lysis syndrome (TLS) is a rare but life-threatening complication of chemo-
therapy in patients with solid tumors such as colorectal cancer. Combination therapy
comprising infusional irinotencan, 5-fluorouracil (5-FU), with folinic acid (FOLFIRI) and bevaci-
zumab is considered the first choice for metastatic colorectal cancer. Reports of TLS after
therapy with FOLFIRI and bevacizumab are rare. Here we report a case of TLS in a patient with
metastatic colon cancer and peritoneal carcinomatosis, which developed 4 days after FOLFIRI
and bevacizumab combination therapy. The patient died of acute renal failure 7 days after
chemotherapy despite aggressive medical treatment. The large tumor burden, rapid prolifer-
ation of cancer cells, and azotemia prior to chemotherapy indicated a high risk of developing
TLS in our patient. Although rare, steps to prevent TLS and to manage it aggressively if it oc-
curs are required, especially for high-risk patients.
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Tumor lysis syndrome (TLS) is a potentially life-threatening
complication of chemotherapy. The incidence and mortal-
ity rate depend on tumor burden, drug sensitivity, and renal
insufficiency or dehydration prior to chemotherapy.1 It isciation. Published by Elsevier Taiwan LLC. All rights reserved.
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but rarely with solid tumors such as breast cancer, lung
cancer, sarcoma, ovarian cancer, and colon cancer.2 Here
we report a case of TLS in a patient who was diagnosed with
nonresectable ascending colon cancer with liver metastasis
and peritoneal carcinomatosis. The patient developed TLS
following palliative chemotherapy with infusional irino-
tencan, 5-fluorouracil (5-FU), and folinic acid (FOLFIRI)
combined with bevacizumab.2. Case report
An 80-year-old man was initially evaluated on April 16,
2012, for a 2-day history of abdominal fullness with pain,
diarrhea, and intermittent fever. Because of positive re-
sults for a stool occult blood test, a colonoscopy was per-
formed, which revealed an ulcerative tumor at the hepatic
flexure. A colorectal physician was consulted for further
evaluation. A preoperative computed tomography scan of
the abdomen without contrast medium (owing to renal
function impairment) revealed increased soft-tissue density
in the distal ascending colon adjacent to the hepatic
flexure with local lymphadenopathy. We performed surgical
intervention on April 25 for a diagnosis of colon cancer with
obstruction (clinical stage T4N2Mx). After opening the
peritoneal cavity, multiple whitish miliary lesions were
seen on the mesentery of the small intestine, omentum,
and peritoneal surface of the abdominal wall. Multiple
whitish, palpable mass lesions in Segment 5 (S5) of the liver
were also noted. Because a diagnosis of ascending colon
cancer with liver metastasis and peritoneal carcinomatosis
was evident, we performed loop ileostomy for management
of the obstruction and an excisional biopsy of the perito-
neal tumor seeding. Conservative treatment improved the
bowel obstruction and acute renal failure, and creatinine
levels decreased from 2.95 mg/dL to 1.55 mg/dL. The pa-
tient was discharged on May 23, 2012. Because of the
diagnosis of metastatic colon cancer, the patient received
biological therapy with bevacizumab (Avastin). Laboratory
tests prior to chemotherapy revealed a white blood count
(WBC) of 15400/mL, total neutrophil count of 12243/mL, an
increase in creatinine from 1.55 mg/dL to 2.94 mg/dL, and
total bilirubin of 0.37 mg/dL. The patient received a first
course of palliative chemotherapy consisting of bev-
acizumab (5 mg/kg; total dose 300 mg) and the FOLFIRI
regimen from June 5 to June 7, 2012. The patient’s body
surface area was 1.64 m2 (body weight 59.4 kg, height
1.63 m). We reduced the standard dose of irinotecan by 20%
because of the patient’s impaired renal function (from
180 mg/m2 to 144 mg/m2; total dose 236 mg). The doses of
5-FU and folinic acid were not changed. The patient
tolerated the infusion well, with mild nausea and poor
appetite. During hospitalization, his carcinoembryonic an-
tigen (CEA) level increased from 8.78 ng/mL to 45.22 ng/
mL, and cancer antigen (CA) 19-9 increased from 574 mEq/
L to 15,376 mEq/L. On June 9, 2012, the patient was
admitted to our emergency department for vomiting of
coffee ground material and passage of tarry stools via
ileostomy. His WBC count was 24,100/mL, aspartate
aminotransferase (AST) was 30 U/L, blood urea nitrogen
was 105.4 mg/dL, creatinine had increased from 2.94 mg/dL to 7.95 mg/dL, and potassium had increased from
4.18 mEq/L to 5.44 mEq/L. Because of these abnormal test
results, dehydration-induced acute renal failure associated
with upper gastrointestinal tract bleeding or neutropenic
sepsis associated with irinotecan was not deemed likely,
and TLS was considered. We evaluated the biochemical
data associated with TLS and noted that the patient’s levels
of uric acid, calcium, and phosphorus were 18.94 mg/dL,
7.46 mg/dL, and 9.16 mg/dL, respectively, and potassium
had increased from 5.44 mEq/L to 5.66 mEq/L. The patient
also developed metabolic acidosis and hypotension. His
biochemical profile was consistent with acute TLS. The
patient’s oxygen saturation progressively deteriorated and
his level of consciousness decreased. Intensive intervention
including endotracheal intubation with mechanical venti-
lator support or hemodialysis was recommended; however,
the patient’s family refused this proposal, giving up any
hope for the terminal stage of colon cancer. Respiratory
failure gradually exacerbated and the patient eventually
died of complications associated with TLS 7 days after
chemotherapy.3. Discussion
According to National Comprehensive Cancer Network
guidelines, version 3.2013, approximately 50e60% of pa-
tients diagnosed with colorectal cancer develop colorectal
metastases, and 80e90% of these patients have non-
resectable metastatic liver disease. However, it has been
shown that patients with resectable metastatic liver tumors
can be cured (disease-free survival rate 20%). Palliative
primary resection is rarely indicated in patients presenting
with nonresectable metastases if there is no obstruction.
Systemic chemotherapy is the preferred initial treatment.
Approximately 17% of patients with metastatic peritoneal
carcinomatosis have a short overall survival rate. The
treatment goal for most patients with peritoneal carcino-
matosis is palliative rather than curative, and consists of
systemic chemotherapy.
TLS is an oncologic emergency characterized by hyper-
uricemia, hyperkalemia, hyperphosphatemia, hypocalce-
mia, and uremia. It occurs as a result of the rapid
destruction of malignant cells, leading to abrupt release of
nucleic acids including purine, intracellular ions, and pro-
teins and their metabolites into the extracellular space.3 It
may occur spontaneously, but occurs more commonly after
cytotoxic chemotherapy, especially in cases of cancers that
are highly sensitive to chemotherapy. Intracellular contents
including purine play an important role in such a situation.
Uric acid is a catabolic product of purine that is soluble in
plasma and poorly soluble in acidic urine. High amounts of
uric acid and calcium phosphate crystals can deposit in the
renal tubules and disrupt normal renal secretion of serum
potassium and phosphate. Finally, this may lead to acute
renal failure.2
TLS has been reported mostly in hematological malig-
nancies and less frequently in solid malignancies such as
small-cell lung carcinoma and breast carcinoma. Never-
theless, TLS is an extremely rare complication in patients
with colorectal cancer treated with chemotherapy or bio-
logical therapy. The risk of TLS is associated with the type
202 M.-H. Hsieh et al.of malignancy, large tumor burden, high proliferative rate
of tumor cells, and tumor chemosensitivity.1 Baeksgaard
et al reported that pretreatment risk factors for TLS in solid
tumors include azotemia, increased lactate dehydrogenase
(LDH), and hyperuricemia.4 Vodopivec et al reviewed 100
cases of TLS in solid tumors. The dominant risk factor for
TLS was large tumor burden, which occurred in all the 100
cases. Another relevant fact was the presence of meta-
static disease, observed in 83% of all cases, in which the
liver was the most commonly affected organ.5 Our patient
had impaired renal function (blood urea nitrogen 44 mg/dL,
creatinine 2.94 mg/dL) before chemotherapy, a large
tumor burden, and liver metastases, which indicated a high
risk of developing TLS.
Current management of disseminated metastatic colon
cancer involves various chemotherapeutic drugs, used
either in combination or as single agents: 5-FU/folinic acid,
capecitabine, irinotecan, oxaliplatin, bevacizumab, and
cetuximab. The choice of therapy is based on the type and
timing of prior therapy, the goal of therapy, and the toxicity
of the constituent drugs. The two most common thera-
peutic regimens are 5-FU/LV in combination with either
FOLFIRI or oxaliplatin plus infusional 5-FU/LV (FOLFOX). A
combination of bevacizumab, a humanized antibody that
blocks vascular endothelial growth factor, with either
FOLFOX or FOLFIRI is considered an appropriate intensive
therapy in the absence of a particular contraindication.
Irinotecan should be used with caution and at a decreased
dose in patients with Gilbert syndrome or in patients with
elevated serum bilirubin levels. Bevacizumab may interfere
with wound healing and increase the risk of gastrointestinal
perforation.
TLS is rarely associated with colorectal cancer and only a
few cases have been reported in the past two decades.
Three TLS cases were described after irinotecan-containing
therapy (single irinotecan or FOLFIRI regimen).6e8 Another
case of TLS was noted after cetuximab therapy.3 Only one
published study described TLS after FOLFIRI/bevacizumab
in combination with chemotherapy in a patient with met-
astatic colon cancer. In this patient, FOLFIRI and bev-
acizumab therapy was the fifth line of treatment. The
patient received 5-FU and folinic acid (Mayo regimen),
capecitabine, FOLFOX, and FOLFIRI treatment for more
than 10 years after primary diagnosis of metastatic colon
cancer. He developed TLS after the fifth line of treatment
with FOLFIRI and bevacizumab and died of acute renal
failure.9 Our patient developed TLS within 48 hours of the
first course of chemotherapy with FOLFIRI and bevacizumab
and eventually died of fatal complications. Bevacizumab is
currently suggested as the first-line treatment for meta-
static colorectal carcinoma; therefore, the incidence of
TLS after bevacizumab combination chemotherapy may
increase in the future.
A method for adjusting irinotecan doses in patients with
impaired renal function has still not been established. In
studies that demonstrated the safety of chemotherapy for
colorectal cancer, patients with renal function impairment
were often excluded. Venook et al reported that patients
with elevated AST and creatinine levels did not show
increased sensitivity to irinotencan, and dosage reduction
was only recommended for patients with elevated bilirubin
levels prior to chemotherapy.10 de Jong et al reported thatrenal function was a predictor of hematologic toxicity of
irnotecan. Patients with a low creatinine clearance rate
(35e66 mL/min) had a 2.5 times higher risk than those with
grade 3e4 neutropenia (47.1% vs. 18.8%). However, expo-
sure to irinotecan (7-ethyl-10-[4-(1-piperidino)-1-
piperidino]carbonyloxycamptothecin; CPT-11) and its
active metabolite SN-38 (7-ethyl-10-hydroxycamptothecin)
was not found to be related to renal function.11 In our pa-
tient, we reduced the standard dose of irinotecan by 20%,
and despite TLS development, no neutropenia was found.
Thus, the relationship between TLS and the irinotecan dose
in patients with impaired renal function remains unclear.
Appropriate management of TLS includes risk assess-
ment, fluid management for TLS prophylaxis, and drug
therapy. Fluid management is the key to TLS prevention.
Aggressive hydration and maintenance of normal urine
output are important in decreasing uric acid deposition in
the renal tubules to prevent acute urate nephropathy. Di-
uretics can be administered when urine output mainte-
nance is required. Allopurinol is used to prevent the
formation of uric acid by inhibition of xanthine oxidase,
which converts xanthine into hypoxanthine and then into
uric acid. However, allopurinol is ineffective in reducing
uric acid levels and increasing the xanthine and hypoxan-
thine levels; it can also promote obstructive uropathy.
Rasburicase reduces serum uric acid levels more rapidly
than allopurinol via enzymatic degradation of uric acid to
allantoin, which is highly soluble. Rasburicase is an FDA-
approved drug for the management of patients with ma-
lignancies who are receiving anticancer therapy that could
result in TLS. Urine alkalinization (maintaining urine
pH > 7) is used to increase the solubility of uric acid in urine
to decrease potential deposition of urate crystals. One
disadvantage of urine alkalinization is that it increases the
risk of calcium phosphate deposition in the kidney. There-
fore, urine alkalinization is suggested only for patients with
metabolic acidosis. Electrolyte monitoring in patients un-
dergoing cytotoxic therapy and rapid appropriate thera-
peutic intervention are important. Ultimately, dialysis may
be needed if severe renal failure, electrolyte imbalance,
and metabolic derangement occur.1,2,12
In our patient, we only performed ileostomy for stool
diversion without tumor resection. The bulky tumor with
liver metastasis, peritoneal carcinomatosis, and rapidly
increasing CEA and CA 19-9 levels were suggestive of a high
proliferative rate for the tumor cells. Renal function
insufficiency prior to treatment was also noted. These are
all factors that increase the risk of developing TLS, and we
should have considered more tolerable palliative treatment
for this patient. Because of his advanced age and relatively
high risk of developing TLS, aggressive chemotherapy
(FOFIRI and bevacizumab) would have been inappropriate
and TLS preventive measures should have been taken
before chemotherapy.
In summary, it is important to pay close attention to the
possibility of TLS risk after FOLFIRI and bevacizumab-
containing chemotherapy in patients with metastatic
colorectal cancer, especially for relatively high-risk pa-
tients. The risk of TLS is associated with the type of ma-
lignancy, large tumor burden, high proliferative rate of
tumor cells, and tumor chemosensitivity. Although rare,
steps to prevent TLS prior to chemotherapy and aggressive
Fatal tumor lysis syndrome 203management if it occurs are necessary to prevent acute
renal failure and decrease the mortality rate.
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